We’ve put some small files called cookies on your device to make our site work.
We’d also like to use analytics cookies. These send information about how our site is used to a service called Google Analytics. We use this information to improve our site.
Let us know if this is OK. We’ll use a cookie to save your choice. You can read more about our cookies before you choose.
Your feedback matters and will make a difference.
Help us understand your digital experience by taking our 10 minute survey. Your responses are completely anonymous.
Start the survey.
Clinical Commissioning Policy: Sodium oxybate for symptom control of narcolepsy with cataplexy (children)
This document describes the evidence that has been considered by NHS England in formulating a policy to routinely commission sodium oxybate for a defined group of children (≤18 years old) suffering from narcolepsy with cataplexy who have reached puberty and who have not responded, or are intolerant to, first and second line medications.
